Matthew C. Abernethy

2019

In 2019, Matthew C. Abernethy earned a total compensation of $5.8M as Chief Financial Officer at Neurocrine Biosciences, a 117% increase compared to previous year.

Compensation breakdown

Bonus$284,970
Option Awards$3,750,345
Salary$495,600
Stock Awards$1,250,035
Other$42,170
Total$5,823,120

Abernethy received $3.8M in option awards, accounting for 64% of the total pay in 2019.

Abernethy also received $285K in bonus, $495.6K in salary, $1.3M in stock awards and $42.2K in other compensation.

Rankings

In 2019, Matthew C. Abernethy's compensation ranked 1,788th out of 13,971 executives tracked by ExecPay. In other words, Abernethy earned more than 87.2% of executives.

ClassificationRankingPercentile
All
1,788
out of 13,971
87th
Division
Manufacturing
638
out of 5,692
89th
Major group
Chemicals And Allied Products
193
out of 2,189
91st
Industry group
Drugs
155
out of 1,875
92nd
Industry
Biological Products, Except Diagnostic Substances
36
out of 389
91st

Pay ratio

Matthew C. Abernethy's Pay$5,823,120
Median Employee's Pay$257,209
Pay Ratio

23

to 1

In 2019, the annual total compensation of Matthew C. Abernethy was $5,823,120.

The annual total compensation of the median employee at Neurocrine Biosciences was $257,209.

The ratio of Matthew C. Abernethy's pay to the pay of median employee was therefore 23 to one.

Source: SEC filing on April 9, 2020.

Abernethy's colleagues

We found five more compensation records of executives who worked with Matthew C. Abernethy at Neurocrine Biosciences in 2019.

2019

Kevin Gorman

Neurocrine Biosciences

Chief Executive Officer

2019

Eric Benevich

Neurocrine Biosciences

Chief Commercial Officer

2019

Eiry Roberts

Neurocrine Biosciences

Chief Medical Officer

2019

Haig Bozigian

Neurocrine Biosciences

Chief Development Officer

2019

Kyle Gano

Neurocrine Biosciences

Chief Development and Strategy Officer

News

In-depth

You may also like